PMEPA1 guards against TGF-β-mediated prostate cancer bone metastasis

doi:10.1016/j.ajur.2015.11.002

Asian Journal of Urology, 2016, 3 (1): 1-3 doi: 10.1016/j.ajur.2015.11.002

Research Highlight

Current Issue | Archive | Adv Search

PMEPA1 guards against TGF-β-mediated prostate cancer bone metastasis

Alexandra M. Blee, Haojie Huang

Department of Biochemistry and Molecular Biology, Mayo Graduate School, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN, USA

Abstract
Related Citation (0)

Download:

HTML

PDF (935KB)
Export: BibTeX | EndNote (RIS)

Abstract In advanced-stage prostate cancer, bone metastases are often incurable and cause chronic pain, bone fractures, and decreased quality of life. Researchers have previously identified that transforming growth factor-b (TGF-b) signaling is an important regulator of bone metastases in prostate cancer and that targeting TGF-b signaling is a promising therapeutic strategy [1,2].

Received: 08 November 2015 Published: 29 January 2016

Corresponding Authors: Haojie Huang E-mail: huang.haojie@mayo.edu

	Service
	E-mail this article
	Add to citation manager
	E-mail Alert
	Articles by authors
	Alexandra M. Blee
	Haojie Huang

TRENDMD:

Cite this article:

Alexandra M. Blee,Haojie Huang. PMEPA1 guards against TGF-β-mediated prostate cancer bone metastasis[J]. Asian Journal of Urology, 2016, 3(1): 1-3.

URL:

http://www.ajurology.com/EN/10.1016/j.ajur.2015.11.002 OR http://www.ajurology.com/EN/Y2016/V3/I1/1

[1]	Hu Z, Gupta J, Zhang Z, Gerseny H, Berg A, Chen Y, et al. Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-beta inhibits established bone metastasis in a prostate cancer mouse model. Hum Gene Ther 2012; 23:871-82.
[2]	Wan X, Li ZG, Yingling JM, Yang J, Starbuck MW, Ravoori MK, et al. Effect of transforming growth factor beta (TGF-beta) receptor I kinase inhibitor on prostate cancer bone growth. Bone 2012;50:695-703.
[3]	Fournier PG, Juarez P, Jiang G, Clines GA, Niewolna M, Kim HS, et al. The TGF-beta signaling regulator PMEPA1 suppresses prostate cancer metastases to bone. Cancer Cell 2015;27: 809-21.
[4]	Pickup M, Novitskiy S, Moses HL. The roles of TGFbeta in the tumour microenvironment. Nat Rev Cancer 2013;13: 788-99.
[5]	Watanabe Y, Itoh S, Goto T, Ohnishi E, Inamitsu M, Itoh F, et al. TMEPAI, a transmembrane TGF-beta-inducible protein, sequesters Smad proteins from active participation in TGF-beta signaling. Mol Cell 2010;37:123-34.
[6]	Xu LL, Shi Y, Petrovics G, Sun C, Makarem M, Zhang W, et al. PMEPA1, an androgen-regulated NEDD4-binding protein, exhibits cell growth inhibitory function and decreased expression during prostate cancer progression. Cancer Res 2003;63: 4299-304.
[7]	Tang LY, Yamashita M, Coussens NP, Tang Y, Wang X, Li C, et al. Ablation of Smurf2 reveals an inhibition in TGF-beta signalling through multiple mono-ubiquitination of Smad3. EMBO J 2011; 30:4777-89.
[8]	Sharad S, Ravindranath L, Haffner MC, Li H, Yan W, Sesterhenn IA, et al. Methylation of the PMEPA1 gene, a negative regulator of the androgen receptor in prostate cancer. Epigenetics 2014;9:918-27.